NIH Grants $5.6 Million to Baylor Scientist for Research Into Personalized Bowel Treatments
Research might produce treatments of involving transplants with a few, selected types of bacteria tailored to an individual's microbiome.
The National Institutes of Health (NIH) has awarded researcher Aaron Wright, Ph.D., at Baylor University’s department of biology, a $5.6 million NIH Director’s Transformative Research Award for his work on microbiome research.
Aaron Wright, Ph.D.
The NIH grants the Director’s Transformative Research Award for ground-breaking research that may involve some risk but may potentially disrupt existing scientific models of thought or forge new research avenues. Wright will partner with Randy Longman, M.D., Ph.D., director of the Jill Roberts Center for Inflammatory Bowel Disease and associate professor at Weill Cornell Medicine, and Chun-Jun Guo, Ph.D., assistant professor in the Jill Roberts Center and associate professor at Weill Cornell Medicine, on a project exploring a personalized approach to the microbiome that may yield new treatments for gut disorders.
The microbiome is made up of colonies of bacteria and other microbes living throughout the body, especially in the gastrointestinal tract. Although it generally performs the same function, each person’s microbiome is unique based on factors, such as diet, environment, genetics, medications, birth circumstances and other determinants.
Wright and his colleagues are conducting research to develop a method to measure individual microbiome activity to potentially identify deficits or overactivity that may contribute to digestive disorders, including ulcerative colitis, Crohn’s disease, and irritable bowel syndrome. The research team is looking to develop ways to identify specific bacteria that may be used in individualized fecal microbiota transplantations.
“No longer would you be depositing an entire fecal sample but taking a select handful of [bacteria] that you could transplant. That’s again the long-term goal: to treat different intestinal issues through personalized therapeutics,” said Wright in a news release.
Entyvio Associated With Lowest Risk of Adverse Events in Patients with UC, Study Finds
October 2nd 2024Treatment with Entyvio (vedolizumab), an integrin receptor antagonist, followed by Humira (adalimumab), a tumor necrosis factor blocker, resulted in the lowest overall incidence of adverse events, according to an industry-sponsored study.
Read More
The News About IBD Among Historically Marginalized People Is Not Good
September 19th 2024Results of a survey show that Black/Indigenous/People of Color or Hispanic patients with Crohn's disease or ulcerative colitis were more likely to report poor symptom control and greater difficulty accessing care from specialists and twice as likely to have an IBD-related emergency department visit compared with White non-Hispanic patients.
Read More
